Target ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease)

Target ALS is a privately funded consortium of researchers from academic and biotech/pharma laboratories entirely focused on finding a treatment for patients living with ALS. The association funds research consortia, Springboard Fellowships for emerging research leaders, and nationwide core facilities.

David Rubenstein is one of the founding donors for Target ALS research.
Dan Doctoroff, David Rubenstein, and Bloomberg Philanthropies Unveil Target ALS